alexa Targeting Human β-Microglobulin with Monoclonal
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

Targeting Human β-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment

Mingjun Zhang1,2, Jin He1 and Jing Yang1,3*

1Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

2Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, USA

3Cancer Research Institution, Guangzhou Medical University, Guangzhou, China

*Corresponding Author:
Jing Yang
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson
Cancer Center, Texas, USA
Tel: 713-563-0357
Fax: 713-745-1179
E-mail: [email protected]

Received date: January 21, 2016; Accepted date: February 16, 2016; Published date: February 20, 2016

Citation: Zhang M, He J, Yang J (2016) Targeting Human β-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment. Chemo Open Access 5:190. doi: 10.4172/2167-7700.1000190

Copyright: © 2016 Zhang M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Multiple myeloma (MM) is a clonal plasma cell neoplasm that utilizes bone marrow microenvironment for survival and proliferation [1-3]. However, current therapies could rarely cure MM. The relapse or refractory aspect of the disease is commonly seen in MM patients, especially among patients with high-risk MM. In past decades, targeted immunotherapy with monoclonal antibodies (mAbs) emerged as a major new treatment modality that offered great benefits for MM patients [4]. Different approaches, aimed at finding potential mAbbased therapeutics for this disease including identification of alternative, or novel, target antigens [5], conjugation of mAbs with classic or novel drugs [6], and generation of chimeric antigen receptor T cells with specific mAbs [7], have been developed by scientists. Recently, our group has generated the mAbs that work directly against human β2-microglobulin (β2M) both in vitro and in the mouse experiments, and has demonstrated that β2M is a potential target for MM treatment [8].

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords